790667-43-5

Basic information

• Product Name: 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2R)-(9CI)
• Synonyms: 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2R)-(9CI);(2R)-2-Methyl-4-oxo-piper...;(2R)-2-Methyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester;1-N-boc-2(R)-Methyl-piperidin-4-one;tert-butyl (2R)-2-methyl-4-oxopiperidine-1-carboxylate;1-Piperidinecarboxylic acid, 2-methyl-4-oxo-, 1,1-dimethylethyl ester, (2R)-;(R)-tert-butyl 2-methyl-4-oxopiperidine-1-carboxylate;(R)-2-Methyl-4-oxopiperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 790667-43-5
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.28
• Product Categories: METHYL
• Mol File: 790667-43-5.mol

Chemical Properties

• Melting Point: 57.7 °C
• Boiling Point: 298.8±33.0 °C(Predicted)
• Appearance: /
• Density: 1.060±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.52±0.40(Predicted)
• CAS DataBase Reference: 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2R)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2R)-(9CI)(790667-43-5)
• EPA Substance Registry System: 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2R)-(9CI)(790667-43-5)

Safety Data

• Hazardous Substances Data: 790667-43-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2R)-(9CI) is used as a building block for the synthesis of various drugs and drug candidates. Its versatile chemical structure allows for the development of new therapeutic agents with potential applications in treating a range of diseases and conditions.
Used in HIV Protease Inhibitor Synthesis:
In the field of antiretroviral therapy, 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2R)-(9CI) is used as a key intermediate in the synthesis of potential HIV protease inhibitors. These inhibitors play a crucial role in the treatment of HIV/AIDS by blocking the activity of the HIV protease enzyme, thereby preventing the maturation of the virus and limiting its ability to infect new cells.
Used in Synthesis of Bioactive Compounds:
1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2R)-(9CI) is also utilized as a precursor in the synthesis of various bioactive compounds. Its unique chemical properties enable the creation of novel molecules with potential applications in medicine, such as analgesics, anti-inflammatory agents, and other therapeutic agents.

Upstream product

• 71322-99-1 2-methyl-4-oxopiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 325486-45-1 tert-butyl 4-oxo-3,4-dihydropyridine-1(2H)-carboxylate 
• 75-24-1 trimethylaluminum 
• 89467-37-8 (R)-2-methyl-1-((S)-1-phenylethyl)piperidin-4-one 
• 190906-92-4 tert-butyl 2-methyl-4-oxopiperidine-1-carboxylate 

Downstream Products

• 790667-44-6 tert-butyl (2R,4R)-4-hydroxy-2-methylpiperidine-1-carboxylate 
• 790668-06-3 (2R,4S)-tert-butyl 4-hydroxy-2-methylpiperidine-1-carboxylate 
• 1691250-97-1 (2R)-tert-butyl 4-amino-2-methylpiperidine-1-carboxylate 
• 1691250-97-1 tert-butyl (2R,4R)-4-amino-2-methylpiperidine-1-carboxylate 

Relevant articles and documents

N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF

A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: (I) wherein R1, R2, R3, A, L, m, n, p and q are as defined herein.

A chiral 2 - substituted - 4 - piperidone - 1 - carboxylic acid tert-butyl synthetic method

The invention discloses a synthetic method of chiral 2-substitute-4-piperidone-1-carboxylic acid tert-butyl ester. The synthetic method comprises the following steps: (1) an esterification reaction: carrying out a reaction between chiral beta-amino acid, and thionyl chloride and methanol to obtain chiral beta-amino acid methyl ester hydrochloride; (2) a Michael addition and tert-butyloxycarboryl protecting reaction: carrying out a Michael addition reaction between chiral beta-amino acid methyl ester hydrochloride and methyl acrylate to obtain a substance, and then carrying out a reaction between the substance and di-tert-butyl dicarbonate to obtain chiral 3-substitute-3-(tert-butyloxycarboryl(3-methyl propionate)amino)methyl propionate; (3) a lactone condensation and decarboxylation reaction: conducting lactone condensation and decarboxylation on chiral 3-substitute-3-(tert-butyloxycarboryl(3-methyl propionate)amino)methyl propionate to obtain chiral 2-substitute-4-piperidone-1-carboxylic acid tert-butyl ester. The synthetic method is simple to operate, higher in yield, low in raw material cost, highly available, and suitable for industrialized production.

Catalytic asymmetric synthesis of the alkaloid (+)-myrtine

A new protocol for the asymmetric synthesis of trans-2,6-disubstituted-4- piperidones has been developed using a catalytic enantioselective conjugate addition reaction in combination with a diastereoselective lithiation- substitution sequence; an efficient synthesis of (+)-myrtine has been achieved via this route.

MCH antagonists for the treatment of obesity

The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure: where the substituents are as defined herein.

(PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT1F AGONISTS

The present invention relates to compounds of formula 1: and pharmaceutically acceptable acid addition sails thereof. The compounds of the present invention are useful for activating 5-HTIF receptors, inhibiting neuronal protein extravasation, and for the treatment or preverition of migraine in mammals, particularly humans.